IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
ER-Negative Breast Cancer
Jules Bordet Institutemonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
18 Active assets in the ER-Negative Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Northwestern University | Phase 3 | BBB |
Epirubicin Massachusetts General Hospital | Phase 2 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II University of Washington | Phase 3 | BB |
Pembrolizumab Massachusetts General Hospital | Phase 2 | BB |
Irinotecan Sanofi | Phase 3 | BB |
View all 50 →
Same molecule, other indications
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →